Pluristyx Secures $2 Million in Funding from BioLife Solutions.

Pluristyx, Inc. has received $2 million in funding from BioLife Solutions, Inc. The funding was in the form of convertible notes issued on July 28, 2025, with BioLife participating in the round. As part of the investment, BioLife will have a board observer seat and certain rights related to a potential future acquisition.

BOTHELL, Wash. - BioLife Solutions, Inc. (NASDAQ: BLFS) has announced a strategic investment of $2 million in convertible notes in Pluristyx, Inc., a Seattle-based developer of induced pluripotent stem cell (iPSC) products for cell therapy developers. The investment, which was part of a larger financing round, was announced on July 28, 2025 [1].

As part of the agreement, BioLife will receive a board observer seat and certain rights related to any potential future acquisition of Pluristyx. The investment follows BioLife's previous strategic investments in Sexton and PanTHERA, aligning with the company's broader interest in exploring biological assays as a product portfolio adjacency [2].

Roderick de Greef, BioLife's Chairman and CEO, remarked, "We have known and worked with the founding team at Pluristyx for many years, and we have a great deal of respect for their scientific expertise in cell therapy. Their recent development of an iPSC-based biological assay for organoid manufacturing dovetails with our interest in exploring biological assays more broadly as a product portfolio adjacency."

Benjamin Fryer, PhD, Pluristyx's CEO, commented, "It is gratifying to have BioLife Solutions validate our vision with its investment. Their support will allow us to manufacture, commercialize, and distribute our innovative solutions and help our customers solve critical industry challenges."

Pluristyx focuses on developing cell-based tools and therapies, offering products such as PluriKit, PluriForm Organoids, and PluriBank stem cells with various safety features. BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets, helping maintain the health and function of biological materials during collection, development, storage, and distribution processes.

BioLife Solutions reported its Q1 2025 earnings, surpassing expectations with an earnings per share (EPS) of -$0.01 compared to the forecasted -$0.05. The company's revenue for the quarter reached $23.9 million, exceeding the anticipated $21.6 million. These results highlight a strong performance for the company in the first quarter of 2025 [2].

The strategic investment in Pluristyx underscores BioLife Solutions' commitment to expanding its product portfolio and supporting innovative solutions in the cell therapy sector.

References:
[1] https://www.prnewswire.com/news-releases/biolife-solutions-makes-strategic-investment-in-pluristyx-302514454.html
[2] https://www.investing.com/news/company-news/biolife-solutions-invests-2-million-in-stem-cell-developer-pluristyx-93CH-4155192